Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model.
Rafael V Lima Da Cruz, Rêmullo B G de Miranda Costa, Gabriel M De Queiroz, Tijana Stojanovic, Thiago C Moulin, Richardson N Leão
Translational psychiatry January 29, 2026 DOI: 10.1038/s41398-026-03852-7 via PubMed
Summary
AI-generated from the abstractA single dose of the psychedelic DMT reversed depression-like behavior and restored cognitive performance in male mice exposed to chronic stress, outperforming chronic fluoxetine across most measures. When given during the stress period, DMT reduced anhedonia but did not rescue cognitive deficits, indicating domain-specific long-lasting effects. All DMT regimens increased the integration of adult-born granule cells and reduced abnormally integrated cells in the brain, suggesting structural circuit repair. The role of the psychedelic experience remains uncertain because isoflurane anesthesia may have confounded results.
Study at a glance
| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Male mice exposed to chronic unpredictable mild stress |
| Interventions | DMT fluoxetine |
| Dose | 30 mg/kg |
| Citations | 2 |
| Key finding | A single dose of DMT reversed depressive-like behavior and cognitive deficits in stressed male mice and enhanced adult-born granule cell integration, outperforming fluoxetine in most domains. |
Abstract
Major depressive disorder (MDD) remains a leading cause of disability worldwide, with current treatments limited by delayed onset and low efficacy. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) has shown rapid antidepressant effects in early clinical studies, yet its mechanisms and efficacy remain poorly characterized in established models of depression. Here, we evaluated the effects of a single dose of DMT (30 mg/kg, i.p.) in male mice exposed to the Chronic Unpredictable Mild Stress (UCMS) paradigm, a robust mouse model recapitulating key features of MDD, including anhedonia and cognitive impairment. DMT administered after UCMS reversed depressive-like behavior and restored cognitive performance, outperforming chronic fluoxetine across most domains. When administered during the stress period, DMT mitigated anhedonic responses but did not rescue cognitive deficits, suggesting a long-lasting domain-specific efficacy. Exploratory assessments in anesthetized animals showed that DMT's behavioral and cellular benefits persisted under isoflurane, though the role of the psychedelic experience remains uncertain due to potential confounding effects of isoflurane not controlled for in our design. Histological analyses revealed that all DMT regimes significantly increased adult-born granule cell (abGC) integration and reduced the number of ectopically abnormally integrated abGCs. Together, our findings highlight the robust and multifaceted effects of DMT on behavior and neurogenesis, positioning it as a promising candidate for rapid-acting antidepressant strategies that target structural circuit repair.